Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt small index

Hemorrhagic Stroke: early-phase trial registry

6 of 7 indexed Hemorrhagic Stroke trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Hemorrhagic Stroke: 7 US clinical trials tracked, 6 recruiting.

Hemorrhagic Stroke is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is EMVision Medical Devices, running 1 of these trials.

Enrollment posture brief

Registry condition hemorrhagic-stroke

OPEN 6 | RECR 86% | LATE 0 | EARLY 1 | RANK #2497 | SPON 1

Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)

Hemorrhagic Stroke (this)86%ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Hemorrhagic Stroke

Hemorrhagic Stroke lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hemorrhagic Stroke on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hemorrhagic Stroke is recruiting above its size-band peers.

    6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hemorrhagic Stroke trials is spread across many organizations.

    EMVision Medical Devices accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hemorrhagic Stroke enrolment sits around 300 participants.

    Median target enrolment is 300 among the 7 trials that report a genuine target (sentinel values excluded). 2 of those (28.6%) plan for fewer than 100 participants.

  4. Hemorrhagic Stroke splits between interventional and observational designs.

    4 interventional and 3 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Hemorrhagic Stroke records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Matching Placebo for BAF312 tablet Drug
1 trials
BAF312 tablet Drug
1 trials
Matching Placebo for BAF312 solution Drug
1 trials
BAF312 solution Drug
1 trials
Placebo Vagus Nerve Stimulation Device
1 trials
Active Vagus Nerve Stimulation Device
1 trials
Brain Scan Diagnostic test
1 trials
HI-SPEED Protocol Behavioral
1 trials

US sites by state

Facility locations filed on Hemorrhagic Stroke trials. A trial with sites in several states counts in each.

Texas 3 trials
Florida 3 trials
Pennsylvania 2 trials
Ohio 2 trials
New York 2 trials
Georgia 2 trials
Connecticut 2 trials
California 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hemorrhagic Stroke page

7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hemorrhagic Stroke condition card totals 7 registered trials; most-linked intervention Matching Placebo for BAF312 tablet; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.